Harrow Health Inc. (HROW)
33.54
-1.20 (-3.45%)
At close: Jan 14, 2025, 3:59 PM
34.50
2.86%
After-hours Jan 14, 2025, 04:21 PM EST
undefined% (undefined)
| Bid | 31 |
| Market Cap | 1.19B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.95 |
| PE Ratio (ttm) | -35.31 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 37 |
| Volume | 255,542 |
| Avg. Volume (20D) | 492,500 |
| Open | 34.85 |
| Previous Close | 34.74 |
| Day's Range | 32.93 - 35.47 |
| 52-Week Range | 9.13 - 59.23 |
| Beta | undefined |
About HROW
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharma...
Sector Healthcare
IPO Date Sep 28, 2007
Employees 315
Stock Exchange NASDAQ
Ticker Symbol HROW
Website https://www.harrowinc.com
Analyst Forecast
According to 3 analyst ratings, the average rating for HROW stock is "Strong Buy." The 12-month stock price forecast is $55, which is an increase of 63.98% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Harrow Health Inc. is scheduled to release its earnings on Mar 18, 2025,
during market hours.
Analysts project revenue of $59.09M, reflecting a 62.54% YoY growth and earnings per share of 0.07, making a -135.00% decrease YoY.
Analysts project revenue of $59.09M, reflecting a 62.54% YoY growth and earnings per share of 0.07, making a -135.00% decrease YoY.
2 months ago ·
Source
-17.26%
Harrow shares are trading lower after the company ...
Unlock content with
Pro Subscription
2 months ago ·
Source
+3.79%
Harrow shares are trading lower after the company reported worse-than-expected Q3 sales results.
